BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15753649)

  • 21. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
    Bommarito A; Richiusa P; Carissimi E; Pizzolanti G; Rodolico V; Zito G; Criscimanna A; Di Blasi F; Pitrone M; Zerilli M; Amato MC; Spinelli G; Carina V; Modica G; Latteri MA; Galluzzo A; Giordano C
    Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
    Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical prognosis in BRAF-mutated PTC.
    Puxeddu E; Moretti S
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):736-47. PubMed ID: 17891237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.
    Hamatani K; Eguchi H; Ito R; Mukai M; Takahashi K; Taga M; Imai K; Cologne J; Soda M; Arihiro K; Fujihara M; Abe K; Hayashi T; Nakashima M; Sekine I; Yasui W; Hayashi Y; Nakachi K
    Cancer Res; 2008 Sep; 68(17):7176-82. PubMed ID: 18757433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC; Fredrick MJ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
    Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas.
    Lima J; Trovisco V; Soares P; Máximo V; Magalhães J; Salvatore G; Santoro M; Bogdanova T; Tronko M; Abrosimov A; Jeremiah S; Thomas G; Williams D; Sobrinho-Simões M
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4267-71. PubMed ID: 15356020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [BRAF gene mutation in thyroid cancer].
    Kopczyńska E; Junik R; Tyrakowski T
    Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.
    Barollo S; Pezzani R; Cristiani A; Redaelli M; Zambonin L; Rubin B; Bertazza L; Zane M; Mucignat-Caretta C; Bulfone A; Pennelli G; Casal Ide E; Pelizzo MR; Mantero F; Moro S; Mian C
    Thyroid; 2014 May; 24(5):809-19. PubMed ID: 24295088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization.
    Ciampi R; Zhu Z; Nikiforov YE
    Endocr Pathol; 2005; 16(2):99-105. PubMed ID: 16199894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic strategies for targeting BRAF in human cancer.
    Pratilas CA; Solit DB
    Rev Recent Clin Trials; 2007 May; 2(2):121-34. PubMed ID: 18473997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose.
    Takahashi K; Eguchi H; Arihiro K; Ito R; Koyama K; Soda M; Cologne J; Hayashi Y; Nakata Y; Nakachi K; Hamatani K
    Mol Carcinog; 2007 Mar; 46(3):242-8. PubMed ID: 17186541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
    Zafon C; Obiols G
    Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
    Kimura ET; Nikiforova MN; Zhu Z; Knauf JA; Nikiforov YE; Fagin JA
    Cancer Res; 2003 Apr; 63(7):1454-7. PubMed ID: 12670889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
    Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
    Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.
    Faustino A; Couto JP; Pópulo H; Rocha AS; Pardal F; Cameselle-Teijeiro JM; Lopes JM; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1139-49. PubMed ID: 22549934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intracellular signaling mechanisms in thyroid cancer].
    Mondragón-Terán P; López-Hernández LB; Gutiérrez-Salinas J; Suárez-Cuenca JA; Luna-Ceballos RI; Erazo Valle-Solís A
    Cir Cir; 2016; 84(5):434-43. PubMed ID: 27423883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTPN11 Knockdown Prevents Changes in the Expression of Genes Controlling Cell Cycle, Chemotherapy Resistance, and Oncogene-Induced Senescence in Human Thyroid Cells Overexpressing BRAF V600E Oncogenic Protein.
    Putlyaeva LV; Demin DE; Uvarova AN; Zinevich LS; Prokofjeva MM; Gazizova GR; Shagimardanova EI; Schwartz AM
    Biochemistry (Mosc); 2020 Jan; 85(1):108-118. PubMed ID: 32079522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas.
    Lima J; Trovisco V; Soares P; Máximo V; Magalhães J; Salvatore G; Santoro M; Bogdanova T; Tronko M; Abrosimov A; Jeremiah S; Thomas G; Williams D; Sobrinho-Simões M
    Cancer Lett; 2005 Dec; 230(1):149-50. PubMed ID: 16253771
    [No Abstract]   [Full Text] [Related]  

  • 40. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.